Research programme: cancer therapeutics - CiMass

Drug Profile

Research programme: cancer therapeutics - CiMass

Alternative Names: CIM 201; CIM 301; Natural killer cell engaging antibody - CiMass; Natural killer cell therapy - CiMass

Latest Information Update: 16 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CiMass
  • Developer Cancer Research Technology; CiMass; University of Copenhagen
  • Class Antibodies; Bispecific antibodies; Natural killer cell therapies
  • Mechanism of Action Immunostimulants; Natural killer cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Cancer; Multiple myeloma

Most Recent Events

  • 16 Nov 2016 Preclinical trials in Breast cancer (Metastatic disease) in Netherlands (Parenteral)
  • 16 Nov 2016 Preclinical trials in Cancer in Netherlands (Parenteral)
  • 16 Nov 2016 Preclinical trials in Multiple myeloma in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top